Treatment for migraine headache symptoms with sumatriptan (severe, throbbing headaches that sometimes are accompanied by nausea or sensitivity to sound and light). Serotonin 5-HT1 receptors are the only ones that sumatriptan succinate specifically binds to and activates.
The 5-HT1B receptors are stimulated, which causes constriction of the meningeal, dural, cerebral, or pial blood vessels. This lessens vascular pulsation and may help with migraine symptoms. negative consequences: tightness or tingling in the arms, legs, chest, or face. Unusual feelings of heaviness in the chest, arms, or legs. Feelings of warmth or cold in the chest, arms, and legs.
The Global Sumatriptan Succinate Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
The generic versions of Imitrex®1 (sumatriptan succinate) injection, 4 mg and 6 mg single-dose, prefilled syringe autoinjectors, have been made available in the United States, according to a press release from Teva Pharmaceutical Industries Ltd. and Antares Pharma, Inc.
Adults with acute cluster headaches and acute migraine with or without aura can be treated with sumatriptan injection. Self-administered sumatriptan injection is given subcutaneously into the outer thigh or back of the arm.In the United States, migraine and its different symptoms affect about 36 million people.
By their productive cooperation with Antares, they are thrilled to add sumatriptan injection to their expanding offering. “This accomplishment highlights their ability to capitalise on their leadership in the pharmaceutical business, as well as their continued devotion to their patients, customers, and the communities that we serve,” the statement reads.
Teva is still dedicated to expanding its position in the global migraine treatment market and its generic injectable business. Teva keeps putting money into developing new, better-value generic injectable medications.
Teva has the largest portfolio of FDA-approved generic pharmaceuticals, with almost 370 of them now on the market, and it never stops developing new products for the people who need them.
Via their partner, Teva, they are thrilled to make this medicine available to patients in the United States. Given the FDA’s approval and introduction of sumatriptan injectable, they are still enthusiastic about the development of their other joint product initiatives with Teva. These programmes are presently undergoing FDA evaluation.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.